Eureka Therapeutics to Present at Two Upcoming Virtual Conferences

Logo
Oct. 13, 2020 12:00 UTC

 

 
 

EMERYVILLE, Calif.--(BUSINESS WIRE)--Eureka Therapeutics, Inc., a clinical stage biotechnology company developing novel T cell therapies to treat solid tumors, today announced that it will participate virtually in two upcoming conferences in October:

  • TCR-based Therapies Summit
    Title:
    ARTEMIS® Antibody TCR T Cell Therapies for Solid Tumors
    Speaker: Cheng Liu, Ph.D., President and CEO
    Date: Tuesday, October 27, 2020
    Time: 9:00 a.m. EST
  • Cell & Gene Therapy Bioprocessing & Commercialization
    Title:
    Optimizing Viral Vector Production
    Speaker: Nicole Nunez, Ph.D., Process Development Scientist
    Date: Thursday, October 22, 2020
    Time: 8:00 a.m. EST

ABOUT EUREKA THERAPEUTICS, INC.

Eureka Therapeutics, Inc. is a privately held clinical stage biotechnology company focused on developing novel T cell therapies to treat cancers. Its core technology centers around its proprietary ARTEMIS® cell receptor platform and E-ALPHA® antibody discovery platform for the discovery and development of potentially safer and more effective T cell therapies for the treatment of solid tumors and hematologic malignancies. ET140203, the Company’s lead asset, is currently in a Phase I/II US multicenter clinical trial in patients with advanced hepatocellular carcinoma (HCC).

Eureka Therapeutics, Inc. is headquartered in the San Francisco Bay Area. For more information on Eureka, please visit www.eurekatherapeutics.com.

Contacts

Eureka Therapeutics, Inc.
Natalie Liu
Investor Relations
510-318-9215
IR@eurekainc.com

KKH Advisors
Kimberly Ha
917-291-5744
kimberly.ha@kkhadvisors.com

 
 

Source: Eureka Therapeutics, Inc.

Back to news